Cutera has announced the internationally limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate and severe acne. AviClear is a 1726nm laser that targets and suppresses the production of sebum, treating acne at its source. It delivers high power (100W) selectively to the sebaceous glands, the source of sebum production while protecting surrounding tissue through Cutera’s AviCool contact cooling technology.
In an extensive clinical trial cited by Cutera, 92% of patients were deemed responders to the therapy (resolution of at least half of their acne), with a 79% median reduction in inflammatory lesion count at the 12-month mark following the final treatment.
Since its initial launch in North America, AviClear has been used to treat thousands of patients. The technology has received recognition from major beauty publications and garnered numerous awards, including Cosmopolitan’s 2023 Acne Award as Best Pro Treatment for Active Acne.
